• Curative has replaced its enterprise Salesforce (NYSE:CRM) deployment with an in-house, AI powered CRM platform.
• The company terminated a significant Salesforce contract as it shifts to a custom system built around generative AI tools.
• Curative positions the move as a lower cost and more flexible alternative to traditional SaaS CRM offerings.
• Salesforce points to security and compliance demands in regulated sectors as ongoing hurdles for in-house AI systems at scale.

The Curative decision highlights how AI heavy, in-house platforms could reshape demand for third party software, making the broader infrastructure behind those systems worth a closer look through 56 AI infrastructure stocks.

Salesforce provides customer relationship management software that helps companies connect with customers across sales, marketing, and support functions in the US, Europe, and Asia Pacific. As a large US software provider with a market cap of about $157.9b, it is a key reference point when enterprises weigh custom AI systems against established CRM platforms.

How big a deal is Curative replacing Salesforce with its own AI CRM?

Curative walked away from a roughly US$600,000 a year Salesforce contract after building an in-house AI CRM in about two months. For Salesforce, this is a concrete example of a customer deciding that generative AI and internal tools can meet their needs at a lower administrative cost. It puts a spotlight on whether large enterprises see per seat SaaS as flexible enough for fast moving AI projects.

Does this Curative decision change the Salesforce Narrative?

The core Salesforce Narrative leans on AI driven products like Agentforce and Data Cloud increasing stickiness and raising switching costs. Curative’s move points to the opposing risk from that same Narrative, which is that low code and AI automation can commoditise CRM and reduce pricing power if customers believe they can replicate key workflows internally.

If we take a look at the community Narrative for Salesforce, we can see how this news fits into the bigger investment story.

What should you watch next to judge if this matters for Salesforce?

The key test is whether Curative stays an isolated case or if more regulated or mid sized customers announce similar exits from Salesforce or other large CRMs. Over the next few quarters, disclosures around customer churn, contract downsizes, or seat count optimisation linked explicitly to AI tools will be important signposts.

For the full picture including more risks and rewards, check out the complete Salesforce analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.